Prospective, Observational, Multicenter Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation (ANIMA-R)
Latest Information Update: 26 Dec 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ANIMA-R
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 01 Dec 2025 Planned End Date changed from 28 Jun 2026 to 31 Aug 2026.
- 01 Dec 2025 Planned primary completion date changed from 28 Jun 2026 to 31 Aug 2026.
- 08 Aug 2024 Status changed from not yet recruiting to recruiting.